Xolair Offers New Hope for People with Severe Food Allergies

The FDA recently approved an expanded use of the asthma drug Xolair (omalizumab) that could be life-changing for millions suffering from severe food allergies in the US. Xolair, previously only approved for asthma and other conditions, is now the first medication available to help reduce dangerous allergic reactions from accidental exposures to foods like peanuts, tree nuts, milk and eggs.

In a recent clinical trial led by Johns Hopkins, participants receiving Xolair were able to tolerate much higher amounts of allergenic foods without experiencing major allergic symptoms, compared to those receiving placebo injections. Around two-thirds of those studying Xolair’s effects on peanut allergies tolerated nearly half a teaspoon of peanuts, whereas less than 10% of the placebo group could. Similar results were seen for other common food allergens.

How Does Xolair Work?

Xolair functions by blocking the body’s natural allergic inflammatory response. It is a monoclonal antibody that targets immunoglobulin E (IgE), which plays a key role in triggering anaphylaxis. By reducing IgE levels, Xolair is able to decrease the severity of symptoms that occur during accidental exposures to foods like peanuts. While those using Xolair still must strictly avoid allergenic foods, the drug provides a new level of protection from life-threatening reactions.

Side effects of Xolair treatment include injection site reactions and fever in some cases. As with any new medication, patients and doctors will need to weigh the risks and benefits. But for many living in constant fear of a chance exposure, Xolair brings welcome relief and greater peace of mind. Food allergy experts believe 25-50% of those eligible may opt to use Xolair to reduce their risk. As the first FDA-approved treatment of its kind, it offers new hope.